about
Heart failure and Alzheimer's diseaseDemography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem).Differences in routine clinical practice between early and late onset Alzheimer's disease: data from the Swedish Dementia Registry (SveDem).The use of MRI, CT and lumbar puncture in dementia diagnostics: data from the SveDem Registry.Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.Assessment and Reporting of Driving Fitness in Patients with Dementia in Clinical Practice: Data from SveDem, the Swedish Dementia Registry.Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry.Management of Acute Myocardial Infarction in Patients With Dementia: Data From SveDem, the Swedish Dementia Registry.Body Mass Index in Different Dementia Disorders: Results from the Swedish Dementia Quality Registry (SveDem)Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry.Progression of Alzheimer disease in Europe: data from the European ICTUS study.Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry.Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry.Subjective cognitive impairment subjects in our clinical practiceResolution of inflammation is altered in Alzheimer's diseaseSveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice.Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD studyMild cognitive impairment and deficits in instrumental activities of daily living: a systematic review.Age and diagnostic performance of Alzheimer disease CSF biomarkers.Dementia Diagnosis, Treatment, and Care in Specialist Clinics in Two Scandinavian Countries: A Data Comparison between the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry.CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia.Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders.The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified SubjectsNerve growth factor in treatment and pathogenesis of Alzheimer's disease.Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients.Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.The meaning of living close to a person with Alzheimer disease.Diagnosis of Dementia in the Specialist Setting: A Comparison Between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi).The effects of different familial Alzheimer's disease mutations on APP processing in vivo.Body mass index in dementia.Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study.DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study.CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients.Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry.Management of acute ischaemic stroke in patients with dementia.Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers.CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival.Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases.Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
P50
Q26852526-E2CE93A3-1900-4507-B8FF-DD564E407BAEQ30654813-44917D11-4CF3-4271-B6F2-518D2150398AQ30774379-3FFDA1A8-BCB2-4490-B21C-06EBA26104EDQ30865760-86C57CF6-BFA4-4303-A00D-CAA1D2B3E749Q30972921-0CD15833-FE8F-42F0-AEB9-ABC24FB9AB14Q31095046-D183744E-EC1D-46F0-9C77-D16AD805CA26Q31126232-3379A389-F037-4095-9914-EA3D315C0C4CQ31131376-C06457CC-DF65-4392-9BDB-105E58B607AEQ33625739-9A2F160D-6D91-4BFC-9D2D-26B13DB2CF5EQ33892785-20FA1AB3-C72E-46AF-A424-5FB8E6BE705EQ34320212-39CC556C-07B1-42BF-9079-5F95582D9661Q34409929-956032BF-8DE9-4B63-B795-0B8A3202867DQ34630630-D33C5D51-612C-4E56-B0B7-1179A11DC0E7Q34687198-C8083669-BB4E-44A9-845A-9FF01CBB76E0Q34765889-F0FCF414-B75A-4D01-B6D8-88FB7CD163F4Q35103331-7BAF45BF-B07A-4864-A5EE-41F9A4115798Q35120950-A2D559ED-31CC-4EED-B5AB-CA10B47610D9Q35218713-A72DA52E-3F01-443B-9027-EF4989C30521Q35758640-7226C455-390A-4EBA-8F3A-2B0DB5AACC4CQ35786405-9D99915A-5791-47DF-8C86-0C24BC94E26DQ36008217-4F092C2F-C223-46BB-9419-6D800315E4A4Q36361518-BB7C392F-BE43-48AA-B742-64DE20F9882BQ36582235-B2BF7CC5-ACD5-419F-A565-BDE7B505C6A3Q36644201-C9E7BC13-355F-40E8-B260-6959227ECF00Q36662808-B49629FC-9B59-4D96-AA64-32003D1A2054Q37073096-15722537-A71E-49D0-B102-1A2B64347EBBQ37184406-0A778AF3-0066-4ACA-BFD5-F78906C365AAQ37423178-93D882BC-9C08-4CC2-805D-5E483011D023Q37645358-AD3B71AB-24B8-491E-8DFE-87E205BF0DA6Q38255757-2C705913-F54D-4796-89E1-D584AEADAE1BQ38396432-950E673F-F642-4EEF-9617-D4CD7D50505BQ38403214-FDCB833C-BBC9-41C0-BAD0-3883992A172DQ38601719-FB63EF49-7C5A-49F6-931F-FBDA82899CD7Q38639250-2DD378AC-1F4A-44B9-BC3A-C8BACE724987Q38665903-6C53F3BB-1620-4509-AC41-C23BA345ADB3Q38763038-ED31F118-5305-48DC-8528-3EAFFB2731B5Q39182204-56F6877F-52DB-4F33-A3A3-591C39152362Q39469698-5914C16A-0C8C-43E0-8FA1-55A8252B0607Q40495918-E704D30D-A203-47D4-9A07-52B481E90A4EQ40777128-7B53D0FD-CE04-4FAE-B1DC-6A0E7F869D1A
P50
description
Zweeds onderzoekster
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Maria Eriksdotter
@ast
Maria Eriksdotter
@en
Maria Eriksdotter
@es
Maria Eriksdotter
@nl
Maria Eriksdotter
@sl
Maria Eriksdotter
@sq
type
label
Maria Eriksdotter
@ast
Maria Eriksdotter
@en
Maria Eriksdotter
@es
Maria Eriksdotter
@nl
Maria Eriksdotter
@sl
Maria Eriksdotter
@sq
prefLabel
Maria Eriksdotter
@ast
Maria Eriksdotter
@en
Maria Eriksdotter
@es
Maria Eriksdotter
@nl
Maria Eriksdotter
@sl
Maria Eriksdotter
@sq
P214
P906
P1053
I-5427-2015
P21
P214
P27
P31
P3829
P496
0000-0003-2498-4000
P569
1959-01-01T00:00:00Z
P735
P7859
viaf-172655366